摘要
目的:观察2例接受聚乙二醇化干扰素α-2a治疗慢性乙型肝炎患者的临床疗效及安全性。方法:对2例慢性乙型肝炎患者采用聚乙二醇干扰素α-2a单药治疗,治疗过程中定期检测血常规、乙肝五项、HBV-DNA及肝功能指标。结果:例1治疗至12周出现HBeAg阴转,48周实现HBeAg血清学转换,同时HBV-DNA阴转;例2治疗至6周HBV-DNA阴转,12周HBsAg阴转,24周HBsAg血清学转换。结论:聚乙二醇化干扰素α-2a能够在有限的疗程调动免疫反应,获得血清e/s抗原的清除或转换,达到免疫控制,是治疗慢性乙型肝炎的重要治疗手段。
Objective：To observe the clinical efficacy and safety of peginterferon α-2a in treatment of chronic hepatitis B.Methods：Two patients with chronic hepatitis B were treated with peginterferon α-2a;and the blood,HBV viral markers,HBV-DNA and liver function were tested regularly during the therapy.Results：One patient demonstrated negative HBeAg at 12 weeks,HBeAg seroconversion at 48 weeks,and HBV-DNA was undetectable at the same time.The other patient had undetectable HBV-DNA at 6 weeks,negative HBsAg at 12 weeks,and HBeAg seroconversion at 24 weeks.Conclusions：Peginterferon α-2a can regulate the immune response and obtain serum e/s antigens clearance or conversion in a limited treatment course.Peginterferon α-2a is effective on patient with chronic hepatitis B.
出处
《蚌埠医学院学报》
CAS
2010年第10期1015-1017,共3页
Journal of Bengbu Medical College
